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Edited by Stuart FergusonAbstract Cryptococcosis, caused by Cryptococcus neoformans,
is an invasive infection often occurring in AIDS patients. Potent
therapy against HIV, which includes protease inhibitors (PIs),
has beneﬁcial eﬀects also on opportunistic infections by patho-
gens such as C. neoformans and C. albicans. PIs inhibit growth
of C. albicans by aﬀecting the activity of its aspartyl proteases.
We identiﬁed, cloned and sequenced a cDNA from C. neofor-
mans encoding for a putative aspartyl protease (CnAP1), and
the corresponding genomic region. The gene cnap1 codiﬁes for
a protein of 505 aa, with a canonical aspartyl protease structure.
We puriﬁed the recombinant protein and analyzed its activity in
the presence of PIs (Indinavir, Lopinavir, Ritonavir), but did not
evidence any inhibition of protease activity. The transcriptional
level of cnap1 in C. neoformans is constant in diﬀerent media.
The absence of any inhibition activity by PIs suggests that other
targets for PIs might exist in C. neoformans.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cryptococcus neoformans is the causative agent of cryptococ-
cosis, an invasive infection often occurring in HIV-infected and
AIDS patients. Other immunocompromised patients are also at
high risk for cryptococcal infection [1]. Immunological compe-
tent individuals may develop cryptococcosis, although they are
in a minority compared to severely immunocompromised
patients [2–5]. Human infection begins with inhalation of desic-
cated yeasts or basidiospores followed by a local pulmonary
infection. Cryptococcal meningitis is the most commonly
encountered life-threatening manifestation of cryptococcosis;
if untreated, it is always fatal.
Aspartyl proteases, also known as acid proteases (E.C.
3.4.23.X), are a family of proteolytic enzymes present in many
unicellular and multicellular eukaryotes, including vertebrates,
fungi, plants, as well as in some retroviruses, including HIV [2–
5]. Aspartyl proteases are monomeric proteins with two
domains, each containing one aspartic residue essential for
enzymatic activity [6–9]. Most retroviruses, including HIV,*Corresponding author. Fax: +39 059 422 2604.
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tein of 95–125 aminoacids obtained by cleavage of a retroviral
precursor polyprotein [6–9]. Highly active antiretroviral ther-
apy (HAART), which includes HIV protease inhibitors (PIs),
has considerably reduced AIDS progression and mortality.
HAART has beneﬁcial eﬀects on some opportunistic infections
by fungal pathogens, known to be major causes of morbidity
and mortality in AIDS patients. In particular, we have previ-
ously shown that HIV+ patients who experienced a cryptococ-
cal meningitis (CM) taking HAART have a lower risk of
relapse when the CD4 cell count increases to >100 cells/lL,
even in the absence of antifungal maintenance therapy [10].
PIs such as Indinavir, Ritonavir and Lopinavir, largely used
in HAART, are able to exert a direct inhibitory eﬀect on Can-
dida albicans, and indeed fungal growth and pathogenicity are
profoundly aﬀected [11]. C. albicans has numerous genes that
encode for secretory aspartyl proteases (SAPs), with important
pathogenetic role in candidiasis [12–15]. Accordingly, such en-
zymes, that belong to the same class of HIV proteases [6], have
been shown to be sensitive to PIs [15].
C. neoformans is able to produce proteases [16–20], expected
to favour assimilation of nitrogen from proteins, and have been
proposed as potential virulence factor(s), contributing to host
tissue invasion and colonisation by the pathogen. Evidence ex-
ists that C. neoformans can alter its phenotype by passages in
mice [21], and modify its protease production during a three-
year-long persistence in an AIDS patient experiencing recur-
rent cryptococcal meningoencephalitis [22].
We have previously demonstrated that Indinavir is able to
directly inhibit growth and proliferation of C. neoformans
in vitro [23]. In particular, cryptococcal protease activity was
impaired in a time- and dose-dependent fashion; this phenom-
enon was detectable either in laboratory strains or in clinical
isolates. These data suggested that C. neoformans encodes for
proteases whose activity can be inhibited by PIs [23]. In this
study we report the cloning and the characterization of an
aspartic protease (CnAP1) from C. neoformans, one of the pos-
sible target for PIs.2. Materials and methods
2.1. Fungal and bacterial strains
2.1.1. C. neoformans. We employed a C. neoformans encapsulated
ATCC strain (H99) and two encapsulated strain (BPY444 and
BPY445), derived from the wild-type ﬂuconazole-susceptibile clinical
isolate strain BPY22, as detailed elsewhere [22,24,25]. C. neoformansblished by Elsevier B.V. All rights reserved.
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shire, England) by biweekly passages. The plates were kept at room
temperature.
2.1.2. Escherichia coli. We employed the strains JM109 and M15/
pREP4 (derived from the strain K12), grown at 37 C in LB medium
and LB medium with kanamycin 10 lg/ml, respectively. All transfor-
mants were selected on LB media containing 100 lg/ml ampicillin for
JM109 and 100 lg/ml ampicillin and kanamycin 10 lg/ml for M15/
pREP4, and were cultured at 37 C overnight.2.2. Bioinformatic analysis
Cryptococcus sequences homologous to known proteases from C.
albicans were searched using BLAST program available at NCBI Ser-
ver [26]. Double and multiple sequence alignments, research of con-
served motifs, codon preference analysis were performed using
Wisconsin Package Software. Three-dimensional structure of C. neo-
formans protease was built on the basis of canonical aspartyl proteases
(proteinase A from Saccharomyces cerevisiae, endothiapepsin from
Cryphonectria parasitica, pepsin from Sus scrofa and renin from Homo
sapiens) [27–31] using Modeller software [32]. 3D images were realized
using PYMOL software [33].
2.2.1. Isolation of DNA and RNA. DNA was isolated from C. neo-
formans as previously described by bead bashing (for PCR template) in
a mini-bead miller (Mini-Bead beater 3110BX, Biospec Products, Bar-
tlesville, OK, USA) [34]. Total RNA was isolated using RNeasy mini
kit by QIAgen, following instructions supplied by manufacturer.
2.2.2. Preparation of cDNA. cDNA was prepared from total RNA
using Superscript III (Gibco-BRL, Rockville, MD,USA) according to
manufacturer’s instructions.
2.2.3. PCR and sequencing. PCRs were performed using Expand
High Fidelity PCR System (Roche Biochemical, Mannheim, Ger-
many). Full length cDNA was obtained starting from EST sequences
by RACE, using 5 0/3 0 RACE kit (Roche). The region between the 5 0
and 3 0 tags from EST was ampliﬁed by PCR using primers CnAP1Dir
(5 0-AATCCTTCCGACAGTTCC-30) and CnAP1Rev (5 0-ACCCC-
AAATTCCCTATCTTAC-30) and sequenced with the same primers.
cDNA from C. neoformans was sequenced using BigDye 2.0 and run
on ABI Prism 310 Genetic Analyzer. Sequences were analyzed using
GCG Wisconsin Package Software.2.3. Protein puriﬁcation
C. neoformans protease was puriﬁed from E. coli JM109 transformed
with pQE80L-CnAP1 plasmid using Ni-NTA spin columns kit by
QIAgen (Valencia, CA, USA) following manufacturer’s instructions.
In brief, E. coli/pQE80L-CnAP1 was grown at 37 C in agitation in
LB broth until the culture reached an absorbance of 0.6; then protease
expression was induced adding IPTG 1 mM. After 0, 15 min, 30 min,
1, 2 and 3 h, bacteria were collected, resuspended in lysis buﬀer
(50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) and
lysed with lysozyme 1 mg/ml followed by four cycles of sonication
(30 s each) on ice. Lysate was loaded onto columns and washed twice
with wash buﬀer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole,
pH 8.0). 6His tagged protein was recovered with elution buﬀer (50 mM
NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0).
2.3.1. SDS–PAGE and Western blot. Total E. coli protein extract
or puriﬁed protein were separated on 15% (w/v) SDS–PAGE and
transferred to nitrocellulose membranes. Western blot was performed
as described [31], with little modiﬁcations. Primary antibody against
6His tag (Serotec, Raleigh, NC, USA) was diluted 1:1000 and goat
anti-mouse conjugated horseradish peroxidase (HRP) were diluted in
blocking buﬀer (TBS-T with 3% non-fat dry milk). Membranes were
washed three times with TBS-T and antigen/antibody complexes were
detected chemiluminescence followed by autoradiography.
2.3.2. CnAP1 activity assay. Enzymatic activity of puriﬁed CnAP1
was evaluated using EnzCheck Protease Assay Kit (Green ﬂuores-
cence) by Molecular Probes (Eugene, Oregon, USA) following instruc-
tions supplied by the manufacturer. The reaction was carried out at
37 C for 1 h in the presence or not of PIs (IND, LPV, RTV) or Pep-
statinA (PepA) 100 lg/ml; when assay was performed with PIs or
PepA, the ﬂuorescent substrate was added after a pre-incubation of
the samples with inhibitors at 37 C for 15 min. Fluorescence was mea-
sured with a Packard FluorocountTM microplate ﬂuorometer. Values
are indicated as relative activity respect to control (without any inhib-
itor) set arbitrarily as 1.2.3.3. Real time PCR. Real time PCR was performed using UDG
Glicosylase Invitrogen Supermix, following manufacturer’s instruc-
tions, on a ABI Prism 7000 Sequence Detection System (Applied Bio-
systems, Foster City, CA, USA), using TaqMan Technology. Primers
for cnap1 are CnAP1Dir (5 0-GGCTCCCTTTTCCAGGATCTC-3 0)
and CnAP1Rev (5 0-GACATCGTCACATGAGGCAAAG-3 0); Taq-
Man Probe is (5 0-CCTTGGCGGTTACTCGGTGGCTTCC-3 0). Data
were normalized to actin expression, used as a housekeeping gene. Actin
was quantiﬁed using a SYBR green as ﬂuorescent detector, with prim-
ers ActinaDir (5 0-TCCATCCTCCACTAATCCACCTAA-3 0) and
ActinaRev (5 0-CAGCACCTAGCACCCATGATC-3 0). Relative
expression of cnap1 was calculated with the ‘‘deltadelta cycle’’ method
on the basis of the diﬀerence in the threshold cycle of cnap1 and actin,
setting expression level of control sample as 1.3. Results
Using the aminoacid sequence of SAP5 from C. albicans as a
query, we identiﬁed an EST clone (b1f08cn) containing a
cDNA from C. neoformans H99 with signiﬁcant homology
for eukaryotic aspartyl proteases. We used this sequence to
do a BLAST search [26] of the partially completed C. neofor-
mans genome sequence (November 2003 [35]) and we identiﬁed
the genomic region containing the putative aspartyl protease
gene.
Starting from the sequence of the EST, RACE (rapid ampli-
ﬁcation of cDNA ends) was used to extend the 5 0 and 3 0 ends
of the cDNA fragment. Sequencing of the genomic DNA and
the 5 0 and 3 0 RACE cDNA fragments allowed us to deﬁne the
structure of the entire gene, which we named CnAP1. (Gen-
Bank accession number DQ641261; Fig. 1 of Supplementary
data).
The gene includes three introns; all putative intron splice
sites followed 5 0 and 3 0 consensus sequences of GTNNGY
and YAG, respectively [1,36]. The position of the introns were
conﬁrmed by cDNA sequencing. Comparison of the DNA and
cDNA allowed us to identify the polyadenylation site at the
nucleotide 2048 of the full cDNA; no potential polyadenyla-
tion signal sequence was identiﬁed. The ORF encodes a puta-
tive protein, CnAP1, of 505 residues (51.6 kDa), with a
predicted pK of 4.47. A homology search revealed a signiﬁcant
degree of similarity of CnAP1 to several aspartyl proteases:
pepsinogen from Aspergillus oryzae (28% identity; 46% similar-
ity), saccharopepsin from S. cerevisiae (29% identity; 44% sim-
ilarity), aspartic proteinase from Schistosoma japonicum (30%
identity; 45% similarity), SAP5 from C. albicans (28% identity;
35% similarity), among others (Fig. 2 of Supplementary data).
The aspartic residues essential for enzymatic activity were
located at positions 85 and 278, inside two highly conserved
aminoacidic stretches (IVLDTGSSDLWL and AAIDTGTT-
LIGG).
The C term part of the CDS (aa 393–505) does not show any
similarity with known proteins or domains. We have tried to
identify consensus sequence for intracellular traﬃcking or
organelle targeting of the protein, but no similarity emerged
with known consensuses of other species.
The 3D models of the CnAP1 were built with a high degree
of conﬁdence using Modeler software [29], using as a model
the structures of diﬀerent, well-known aspartyl proteases, such
as proteinase A of S. cerevisiae, endothiapepsin from C. par-
asitica, renin and pepsin from H. sapiens Li, 2000 #151;
Coates, 2003 #109; Baldwin, 1993 #148; Fujinaga, 1995
#147; Rahuel, 1991 #149; Sielecki, 1989 #110. 3D homology
Fig. 2. (A) Western blot of CnAP1 expression in Escherichia coli
JM109 plasmid pQE80L-CnAP1 after induction with 1 mM IPTG at
diﬀerent times. The band corresponding to recombinant CnAP1 is
indicated by a black arrow. (B) Western blot of CnAP1, cloned in
E. coli with plasmid pQE80L, puriﬁed with column aﬃnity in native
conditions. The band corresponding to recombinant CnAP1 is
indicated by a black arrow. WF, wash fraction with 10 mM imidazole;
E, eluate in the presence of 200 mM imidazole.
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protein (aa 45–388), whereas the structure of the C term, un-
known domain could not be determined (Fig. 1). Results, very
similar for both algorithms, indicate that an almost complete
structural homology exists between CnAP1 and other aspartyl
proteases in the interface of the catalytic domains and in the
active site. The large part of non-conservative substitutions re-
gards amino acids located on the outer surface of the protein,
whereas the inner core of the enzyme is mostly identical or sim-
ilar to canonical, monomeric aspartyl proteases. In particular,
the sequence and the relative position of the residues necessary
for catalytic activity is completely conserved.
Then we have cloned the entire CDS in pQE80L vector, so
adding an in-frame 6His tag at the N terminus of the protein.
We expressed the recombinant protein in E. coli JM109 carry-
ing the pQE80L-CnAP1 plasmid after induction with IPTG for
3 h. Samples were collected at diﬀerent times to evidence accu-
mulation of recombinant protein. As shown by Western blot
analysis (Fig. 2), a band with an apparent molecular weight
of 49 kDa appears after 15 min of induction with IPTG, and
accumulates until 3 h after adding IPTG to the culture. To-
gether with the major, full length form of the protein, many
other proteins with lower molecular weight, presumably trun-
cated form of CnAP1, accumulated in the cell. The protein
was puriﬁed under denaturing and native conditions using
nickel aﬃnity chromatography, using lysate obtained from
short induction times (15 and 30 min), to avoid premature ter-
mination. Western blots show that the only form of recombi-
nant protein puriﬁed is the full length form. The recombinant
protein was puriﬁed at low levels, probably for the incomplete
exposure of the tag in native conditions. We could not avoid the
copuriﬁcation of other proteins together with 6His CnAP1, de-
spite changes in washing and elution conditions. However, no
protease activity was detected in the column eluate from non-
stimulated samples, indicating that none of the copuriﬁed pro-
teins is an active protease. Test of protease activity indicates
that CnAP1 has a maximum activity at pH 5.0.
We have analyzed the activity of the enzyme in the presence
of three diﬀerent PIs (IND, LPV, RTV), compared to the con-Fig. 1. Three-dimensional ribbon model of CnAP1, built on the basis
of 3D structure of a known aspartyl proteases (proteinase A from
Saccharomyces cerevisiae, endothiapepsin from Cryphonectria parasit-
icafrom, renin from Homo sapiens, pepsin from Sus scrofa). The
catalytic, conserved Asp residues are indicated in blue.trol, at two diﬀerent concentrations (2.5 and 25 lM). As
shown in Fig. 3, we could not evidence any inhibition of pro-
tease activity for all of the three drugs, at both concentrations,
whereas a broad range inhibitor of aspartyl proteases like Pep-
statin A reduced enzymatic activity of about 87% respect to
control.
In order to exclude that the presence of the 6His tag at the N
term of the enzyme could interfere with the activity of the en-
zyme, and so preclude the inhibitory activity of the drugs, we
cloned the CDS of CnAP1 in the vector pQE30-Xa, produced
and puriﬁed the recombinant enzyme in E. coli M15/pREP4.
After proteolytic digestion with Factor Xa, which eliminates
the 6His tag, the enzyme was tested in the presence of PIs;
no inhibition of its activity was observed (data not shown).
Finally, we wondered if cnap1 transcription could be modu-
lated by the presence of proteins in the environment where C.
neoformans is grown. We have analyzed the transcriptional
level of cnap1 in C. neoformans, cultured in a rich medium
(YEPD) and in a minimal medium where proteins were the
sole energy source. As shown in Fig. 4, the expression level
of cnap1 is maintained at similar levels, indicating that pres-
ence of proteins as sole energy source does not inﬂuence tran-
scription of the gene. Furthermore, cnap1 expression seems
depending on the growth phase, with higher expression in sta-
tionary phase than in exponential phase.4. Discussion
We have cloned and characterized an aspartyl protease gene
of C. neoformans, giving for the ﬁrst time the genetic evidence
that this fungus bears gene(s) encoding for this kind of prote-
ases. The C term portion of this protein does not show any
similarity with known proteins, and so its role remains unclear.
We could suppose that this region, like many other domains of
proteases or catabolic enzymes, represents an inhibitor domain
that is cleaved to activate the enzyme, produced as a zymogen,
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Fig. 3. Relative enzymatic activity of CnAP1 in the presence or not of PIs at the indicated concentrations. Relative activity is referred to control
(sample without any drug), arbitrarily set as 1; results are indicated as means ± S.E.M. of three independent experiments. IND, Indinavir; RTV,
itonavir; LPV, lopinavir; PepA, Pepstatin A.
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Fig. 4. Transcriptional levels of cnap1 gene in Cryptococcus neofor-
mans grown in YEPD and minimal medium (Med) for indicated times.
Relative expression is referred to time 0 (before induction) set
arbitrarily as 1.
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nisms by which proteins are distributed inside the Cryptococ-
cus cell are not well known, it is not possible to identify
consensus sequences for organelle targeting or secretion. The
presence of stretches of Ser residues could suggest that this
part of CnAP1 is a target for glycosylation. We are now trying
to express the enzyme in S. cerevisiae and in human, cultured
cells to evaluate a possible glycosylation, and contemporarily
we are producing a truncated form of the enzyme, in order
to evaluate diﬀerences enzymatic activity, and thus clarify
the eventual, inhibitory activity of this domain.
Analysis of the 3D structure of the enzyme, possible only for
the N-term portion of the enzyme (aa 45–388) clearly indicates
that CnAP1 is a canonical aspartic protease, with two homo-
logous domains each containing an Asp residue, located
face-to-face in the centre of the enzyme. The relative position
of the essential residues is perfectly conserved.
We could not evidence any inhibition of protease activity by
HIV PIs even if we have previously shown that IND, a drug
belonging to PI class, can directly inhibit C. neoformans
growth [25]. There are several possible explanations for this re-
sult. The simplest is that CnAP1 is not the direct target of these
drugs, and that other aspartyl proteases existing in C. neofor-
mans represent the real target. We have scanned the C. neofor-
mans cDNA database again, ﬁnding just another one encoding
for a putative aspartyl protease. This gene, that we have named
cnap2, is now under cloning and investigation. However, it isinteresting to note that, compared to C. albicans, C. neofor-
mans has got a lower number of genes encoding for this class
of protease; we can assume that, in the environment where
Cryptococcus has a strong tropism, (secreted?) proteases do
not play the same, crucial role that play in the case of Candida.
Another possible explanation is that since puriﬁed CnAP1
we have analyzed is produced in E. coli, it does not undergo
post translational modiﬁcations. Analysis of the sequence
has evidenced the presence of many putative glycosylation sites
in the C-term portion of the enzyme. We can suppose that in
the absence of such modiﬁcations, the enzyme does not have
the native 3D structure, so changing the accessibility to the
drug, and drug–protein interaction.
As far as transcriptional regulation is concerned, we could
not evidence any signiﬁcant modulation of cnap1 expression
with diﬀerent media, suggesting that C. neoformans has no di-
rect way to regulate the transcription on the basis of the com-
ponent of the medium. However, the observation that cnap1
transcription is increased when C. neoformans reaches the sta-
tionary phase, regardless of the medium considered, indicates
that this gene is eﬀectively regulated and that its protease activ-
ity has probably a role during the lag phase. The discrepancy
between the ability of PIs to inhibit growth of C. neoformans
and the absence of inhibitory activity of this class of drugs
on CnAP1 indicates that further studies are needed to identify
other targets of PIs in this opportunistic pathogen and
better clarify the role of PIs in the control of opportunistic
infections.
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